No

Vaccine, Live Virus

Measles, mumps, and rubella prophylaxis

C

Clinical effects on the fetus: It is not known whether the drug can cause fetal harm or affect reproduction capacity (contracting natural measles during pregnancy can increase fetal risk)

Blood dyscrasias, cancers affecting the bone marrow or lymphatic systems, known hypersensitivity to measles, mumps and rubella vaccine, known hypersensitivity to neomycin, acute infections, and respiratory illness, pregnancy; known hypersensitivity to eggs, chicken or chicken feathers, severely immunocompromised persons

Females should not become pregnant within 3 months of vaccination

MMR vaccine should not be given within 3 months of immune globulin or whole blood

Have epinephrine available during and after administration

MMR vaccine should not be administered to severely immunocompromised persons with the exception of asymptomatic children with HIV (ACIP and AAP recommendation)

Severely immunocompromised patients and symptomatic HIV-infected patients who are exposed to measles should receive immune globulin, regardless of prior vaccination status

The immunogenicity of measles virus vaccine is decreased if vaccine is administered <6 months after immune globulin

Defer immunization during any acute illness

All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967.

Cardiovascular: Edema

Central nervous system: Fever (<100°F)

Local: Burning or stinging, induration

1% to 10%:

Central nervous system: Fever between 100°F and 103°F usually between 5th and 12th days postvaccination

Dermatologic: Rash (rarely generalized)

<1%: Fatigue, convulsions, encephalitis, confusion, severe headache, fever (>103°F - prolonged), palsies, Guillain-Barré syndrome, ataxia, urticaria, itching, reddening of skin (especially around ears and eyes), erythema multiforme, vomiting, sore throat, diarrhea, thrombocytopenic purpura, diplopia, stiff neck, dyspnea, cough, rhinitis, lymphadenopathy, coryza, allergic reactions

Whole blood, interferon immune globulin, radiation therapy, and immunosuppressive drugs (eg, corticosteroids) may result in insufficient response to immunization. DTP, OPV, MMR, Hib, and hepatitis B may be given concurrently; other virus vaccine administration should be separated by greater than or equal to 1 month from measles.

Refrigerate, protect from light prior to reconstitution; use as soon as possible; discard 8 hours after reconstitution

Infants <12 months of age: If there is risk of exposure to measles, single-antigen measles vaccine should be administered at 6-11 months of age with a second dose (of MMR) at >12 months of age

Administer S.C. in outer aspect of the upper arm to children greater than or equal to 15 months of age:

0.5 mL at 15 months of age and then repeated at 4-6 years* of age

In some areas, MMR vaccine may be given at 12 months

*Many experts recommend that this dose of MMR be given at entry to middle school or junior high school

Do not give I.V.

Temporary suppression of TB skin test reactivity with onset approximately 3 days after administration

No information available to require special precautions

No effects or complications reported

Females should not become pregnant within 3 months of vaccination

Federal law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title and address be entered into the patient's permanent medical record

Injection: 1000 TCID₅₀ each of measles virus vaccine and rubella virus vaccine, 5000 TCID₅₀ mumps virus vaccine

Plichta AM, "Immunization: Protecting Older Patients From Infectious Disease," Geriatrics, 1996, 51(9):47-52.